[go: up one dir, main page]

NL2000241A1 - Carboxamidederivaten als muscarine-receptorantagonisten. - Google Patents

Carboxamidederivaten als muscarine-receptorantagonisten.

Info

Publication number
NL2000241A1
NL2000241A1 NL2000241A NL2000241A NL2000241A1 NL 2000241 A1 NL2000241 A1 NL 2000241A1 NL 2000241 A NL2000241 A NL 2000241A NL 2000241 A NL2000241 A NL 2000241A NL 2000241 A1 NL2000241 A1 NL 2000241A1
Authority
NL
Netherlands
Prior art keywords
receptor antagonists
muscarinic receptor
carboxamide derivatives
carboxamide
derivatives
Prior art date
Application number
NL2000241A
Other languages
English (en)
Other versions
NL2000241C2 (nl
Inventor
Paul Alan Glossop
Simon John Mantell
Ross Sinclair Strang
Christine Anne Watson
Anthony Wood
Original Assignee
Pfizer Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Ltd filed Critical Pfizer Ltd
Publication of NL2000241A1 publication Critical patent/NL2000241A1/nl
Application granted granted Critical
Publication of NL2000241C2 publication Critical patent/NL2000241C2/nl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NL2000241A 2005-09-21 2006-09-19 Carboxamidederivaten als muscarine-receptorantagonisten. NL2000241C2 (nl)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US71946705P 2005-09-21 2005-09-21
US71947705P 2005-09-21 2005-09-21
US71946805P 2005-09-21 2005-09-21
US71947705 2005-09-21
US71946705 2005-09-21
US71946805 2005-09-21

Publications (2)

Publication Number Publication Date
NL2000241A1 true NL2000241A1 (nl) 2007-03-22
NL2000241C2 NL2000241C2 (nl) 2009-01-05

Family

ID=37698323

Family Applications (1)

Application Number Title Priority Date Filing Date
NL2000241A NL2000241C2 (nl) 2005-09-21 2006-09-19 Carboxamidederivaten als muscarine-receptorantagonisten.

Country Status (42)

Country Link
US (3) US7772223B2 (nl)
EP (1) EP1928821B1 (nl)
JP (1) JP4221447B1 (nl)
KR (1) KR100976909B1 (nl)
CN (1) CN101268046B (nl)
AP (1) AP1983A (nl)
AR (1) AR055171A1 (nl)
AT (1) ATE420069T1 (nl)
AU (1) AU2006293618B9 (nl)
BR (1) BRPI0616111B8 (nl)
CA (1) CA2623332C (nl)
CR (2) CR9814A (nl)
CU (1) CU20100115A7 (nl)
CY (1) CY1108880T1 (nl)
DE (1) DE602006004768D1 (nl)
DK (1) DK1928821T3 (nl)
DO (1) DOP2006000202A (nl)
EA (1) EA013083B1 (nl)
EC (1) ECSP088265A (nl)
ES (1) ES2318794T3 (nl)
GE (1) GEP20104880B (nl)
GT (1) GT200600422A (nl)
HN (1) HN2006032615A (nl)
HR (1) HRP20090127T3 (nl)
IL (1) IL189453A (nl)
MA (1) MA29839B1 (nl)
ME (1) ME01106B (nl)
MX (1) MX2008002805A (nl)
MY (1) MY143581A (nl)
NL (1) NL2000241C2 (nl)
NO (1) NO340975B1 (nl)
NZ (1) NZ566023A (nl)
PE (1) PE20070460A1 (nl)
PL (1) PL1928821T3 (nl)
PT (1) PT1928821E (nl)
RS (2) RS51680B (nl)
SI (1) SI1928821T1 (nl)
TN (1) TNSN08137A1 (nl)
TW (1) TWI322143B (nl)
UY (1) UY29798A1 (nl)
WO (1) WO2007034325A1 (nl)
ZA (1) ZA200801432B (nl)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008002246A1 (en) * 2006-06-28 2008-01-03 Astrazeneca Ab A pharmaceutical composition comprising an ikk2 inhibitor and a second active ingrdient.
CA2664057A1 (en) * 2006-09-22 2008-03-27 Pfizer Limited Azetidine derivatives as muscarinic receptor antagonists
NZ579056A (en) 2007-03-16 2011-07-29 Pfizer Ltd 5-[3-(3-Hydroxy-phenoxy} -azetidin-1-yl]-5-methyl-2,2-diphenyl-hexanoic acid amide hydrochloride salt
JP5801997B2 (ja) 2009-07-07 2015-10-28 ファイザー・リミテッドＰｆｉｚｅｒ Ｌｉｍｉｔｅｄ 薬品の組合せを吸入するための投薬ユニット、投薬ユニットのパック、および吸入器
WO2012027134A1 (en) * 2010-08-26 2012-03-01 Albemarle Corporation Processes for producing 1-bromo-2 (cyclopropyl methoxy)-5 fluoro-4- methoxybenzene
CN103242214B (zh) * 2013-05-02 2016-04-06 陕西步长高新制药有限公司 一种吲哚衍生物及其制备方法
KR101538846B1 (ko) 2013-07-30 2015-07-22 동아에스티 주식회사 신규한 바이페닐 유도체 및 그의 제조방법
US20200031769A1 (en) * 2017-03-15 2020-01-30 Mylan Laboratories Limited Novel polymorphs of (5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide hydrochloride
PT3691620T (pt) 2017-10-05 2022-10-06 Fulcrum Therapeutics Inc Os inibidores da quinase p38 reduzem a expressão de dux4 e genes a jusante para o tratamento de fshd
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
CN113015721B (zh) 2018-09-19 2025-07-25 科迪华农业科技有限责任公司 毒莠定卤素类似物的制备
CN111423434A (zh) * 2019-01-09 2020-07-17 四川海思科制药有限公司 一种碳酰胺衍生物及其制备方法
WO2020261160A1 (en) * 2019-06-25 2020-12-30 Mylan Laboratories Limited Methods and intermediates for preparing hydrochloride salt of 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
US20230293430A1 (en) 2020-06-26 2023-09-21 Mylan Pharma Uk Limited Formulations including 5-[3-(3-hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenylhexanamide
WO2023049696A1 (en) * 2021-09-21 2023-03-30 Corteva Agriscience Llc Methylation of 2-chloro-6-fluorophenol

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2886574A (en) * 1956-11-19 1959-05-12 Upjohn Co Quaternary ammonium salts of 2, 2-diphenyl-4, 4-dimethyl-4-pyrrolidino-butyramide
US4219559A (en) * 1979-01-10 1980-08-26 Janssen Pharmaceutica N.V. N-Heterocyclyl-4-piperidinamines
GB8824262D0 (en) * 1988-10-17 1988-11-23 Pfizer Ltd Therapeutic agents
US5070087A (en) * 1989-05-08 1991-12-03 A. H. Robins Company, Incorporated Aryl(alkyland alkylene)-N-((phenoxy and phenylthio)alkyl) aminoheterocyclics as cardiovascular, anthihistaminic, antisecretory and antiallergy agents
US5849761A (en) 1995-09-12 1998-12-15 Regents Of The University Of California Peripherally active anti-hyperalgesic opiates
JP4167302B2 (ja) * 1996-12-02 2008-10-15 杏林製薬株式会社 新規ｎ―置換ピロリジン誘導体及びその製造法
DE59611439D1 (de) * 1996-12-17 2007-09-06 Filtertek Bv Rückschlagventil, insbesondere für die Medizintechnik
JPH11100366A (ja) * 1997-09-29 1999-04-13 Kyorin Pharmaceut Co Ltd 新規ｎ−置換環状アミン誘導体及びその製造法
US6673908B1 (en) * 1999-02-22 2004-01-06 Nuvelo, Inc. Tumor necrosis factor receptor 2
GB0011838D0 (en) 2000-05-17 2000-07-05 Astrazeneca Ab Chemical compounds
US6667344B2 (en) * 2001-04-17 2003-12-23 Dey, L.P. Bronchodilating compositions and methods
WO2003053966A2 (en) 2001-12-20 2003-07-03 Laboratorios S.A.L.V.A.T., S.A. 1-alkyl-1-azoniabicyclo [2.2.2] octane carbamate derivatives and their use as muscarinic receptor antagonists
MXPA03000145A (es) 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.
EP1375508A1 (en) 2002-06-27 2004-01-02 Aventis Pharma Deutschland GmbH N6-substituted adenosine analogues and their use as pharmaceutical agents
MXPA05002839A (es) 2002-09-17 2005-05-27 Actelion Pharmaceuticals Ltd Derivados de 1-piridin-4-il-urea.

Also Published As

Publication number Publication date
BRPI0616111A2 (pt) 2011-06-07
ECSP088265A (es) 2008-04-28
PL1928821T3 (pl) 2009-06-30
AU2006293618B9 (en) 2009-10-29
HK1117163A1 (en) 2009-01-09
CN101268046B (zh) 2012-07-25
WO2007034325A1 (en) 2007-03-29
PE20070460A1 (es) 2007-05-14
CN101268046A (zh) 2008-09-17
TWI322143B (en) 2010-03-21
DK1928821T3 (da) 2009-03-16
ZA200801432B (en) 2009-07-29
AR055171A1 (es) 2007-08-08
BRPI0616111B8 (pt) 2021-05-25
PT1928821E (pt) 2009-03-10
MA29839B1 (fr) 2008-10-03
NL2000241C2 (nl) 2009-01-05
IL189453A0 (en) 2008-08-07
US20100029720A1 (en) 2010-02-04
US8486992B2 (en) 2013-07-16
NO340975B1 (no) 2017-07-31
RS20080119A (sr) 2009-05-06
EA200800540A1 (ru) 2008-08-29
UY29798A1 (es) 2007-04-30
MX2008002805A (es) 2008-04-07
EA013083B1 (ru) 2010-02-26
JP2009508933A (ja) 2009-03-05
CA2623332C (en) 2012-05-01
CU20100115A7 (es) 2011-10-14
EP1928821A1 (en) 2008-06-11
SI1928821T1 (sl) 2009-04-30
AP1983A (en) 2009-03-24
CY1108880T1 (el) 2014-07-02
NO20081001L (no) 2008-03-25
MY143581A (en) 2011-05-31
EP1928821B1 (en) 2009-01-07
NZ566023A (en) 2010-02-26
AU2006293618A1 (en) 2007-03-29
DE602006004768D1 (de) 2009-02-26
GT200600422A (es) 2007-05-28
GEP20104880B (en) 2010-01-11
US20070105831A1 (en) 2007-05-10
HN2006032615A (es) 2010-10-04
ATE420069T1 (de) 2009-01-15
JP4221447B1 (ja) 2009-02-12
ME01106B (me) 2013-03-20
US8268881B2 (en) 2012-09-18
DOP2006000202A (es) 2007-04-15
CR9814A (es) 2008-04-16
TW200745024A (en) 2007-12-16
TNSN08137A1 (fr) 2009-07-14
HRP20090127T3 (en) 2009-06-30
ES2318794T3 (es) 2009-05-01
IL189453A (en) 2014-06-30
KR100976909B1 (ko) 2010-08-18
AU2006293618B2 (en) 2009-10-08
CA2623332A1 (en) 2007-03-29
RS50855B (sr) 2010-08-31
RS51680B (sr) 2011-10-31
KR20080037103A (ko) 2008-04-29
BRPI0616111B1 (pt) 2019-10-08
US20110251164A1 (en) 2011-10-13
CR20130209A (es) 2013-09-19
US7772223B2 (en) 2010-08-10
CU23910B1 (nl) 2013-06-29

Similar Documents

Publication Publication Date Title
ATE505467T1 (de) 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
ATE413874T1 (de) Neue thiophen-derivate als sphingosin-1-phosphat- 1-rezeptorantagonisten
ATE555111T1 (de) Chinuclidinol-derivate als muscarinrezeptor- antagonisten
ATE523195T1 (de) Neue thiophen-derivate als sphingosin-1-phosphat- 1-rezeptorantagonisten
NL1032713A1 (nl) Histamine-3-receptorantagonisten.
DE602005027307D1 (de) Arylanilinderivate als agonisten des beta2-adrenergen rezeptors
ATE509928T1 (de) 8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten
ATE481405T1 (de) Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
IL189453A0 (en) Carboxamide derivatives as muscarinic receptor antagonists
NL1028624A1 (nl) Alfa-aryl- of -heteroarylmethyl-bèta-piperidinopropaan-zuurverbindingen als ORL1-receptorantagonisten.
ZA200800320B (en) Indol-3-carbonyl-spiro-piperidine derivatives as Via receptor antagonists
ATE394391T1 (de) Indolderivate als histaminrezeptorantagonisten
ATE512966T1 (de) Pyrazolo-pyrimidin-derivate als mglur2- antagonisten
ATE382034T1 (de) Hydroisoindolin-tachykininrezeptorantagonisten
ATE518834T1 (de) 2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
ATE477243T1 (de) 2-aminochinoline als 5-ht(5a)- rezeptorantagonisten
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
DE60316411D1 (de) Thiazolderivate als npy-rezeptorantagonisten
ATE429428T1 (de) Indanderivate als antagonisten des mch-rezeptors
DE602005009355D1 (de) Gehinderte himbacinanaloga als thrombinrezeptorantagonisten
ATE469900T1 (de) Spiropiperidinderivate als antagonisten des via- rezeptors
DE602006003666D1 (de) Indol-3-ylcarbonylpiperidinbenzimidazolderivate als v1a-rezeptorantagonisten
DE602006015186D1 (de) Oxindole als kinaseinhibitoren
DE602006018645D1 (de) 3-monosubstituiertes tropan-derivat als nociceptinrezeptor-ligand

Legal Events

Date Code Title Description
AD1A A request for search or an international type search has been filed
RD2N Patents in respect of which a decision has been taken or a report has been made (novelty report)

Effective date: 20081030

PD2B A search report has been drawn up
V1 Lapsed because of non-payment of the annual fee

Effective date: 20110401